-
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR NICE HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NEOADJUVANT AND ADJUVANT PEMBROLIZUMAB IN LOCALLY ADVANCED HEAD AND NECK CANCER
Mar 18, 2026, 21:38 PM -
UNMET MEDICAL NEED AND BURDEN OF OBESITY ON PATIENTS, PAYERS, AND HEALTH SYSTEMS IN CANADA, THE USA, AND ENGLAND
Mar 18, 2026, 21:38 PM -
WHY AI PROOF-OF-CONCEPTS DO NOT NECESSARILY PROVE ANYTHING: JOURNEY FROM POC TO PRODUCT
Mar 18, 2026, 21:38 PM -
THE UNINTENDED CONSEQUENCES OF THE INFLATION REDUCTION ACT ON BIOSIMILAR MARKET INCENTIVES AND MEDICARE SAVINGS
Mar 18, 2026, 21:38 PM -
BEYOND THE HEALTH SECTOR: ESTIMATING THE SOCIETAL AND FISCAL IMPACT OF PRIMARY BILIARY CHOLANGITIS IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
A PORTFOLIO MODELING FRAMEWORK FOR HEOR DECISION MAKING
Mar 18, 2026, 21:38 PM -
A MIXED-METHODS STUDY TO EXPLORE THE HEALTH-RELATED QUALITY OF LIFE IMPACT ON CAREGIVERS OF CHILDREN WITH HEREDITARY ANGIOEDEMA
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS, OUTCOMES, AND RESOURCE UTILIZATION IN US ADULTS WITH NF1-PN
Mar 18, 2026, 21:38 PM -
HISTORIC PRICE DIFFERENTIALS AND MOST-FAVORED NATION PRESCRIPTION DRUG PRICING POLICY IMPACT: SCENARIO ANALYSIS USING POLI DATA ACROSS EIGHT GLOBAL MARKETS
Mar 18, 2026, 21:38 PM -
INNOVATIVE GRAPH BASED CLUSTERING TO IDENTIFY SJÖGREN’S DISEASE SUBTYPES FROM REAL-WORLD DIAGNOSTIC JOURNEYS
Mar 18, 2026, 21:38 PM -
EVALUATING INDIVIDUAL-LEVEL ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC-HORMONE SENSITIVE PROSTATE CANCER (MHSPC): AN INDIRECT ILLNESS-DEATH MODELING APPROACH
Mar 18, 2026, 21:38 PM -
COMPREHENSIVE REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) OUTPERFORM CUSTOM REVIEWS FOR STRATEGIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AND MARKET ACCESS (MA) PLANNING: AN ADVANCED METASTATIC BREAST CANCER (MBC) EXAMPLE
Mar 18, 2026, 21:38 PM -
VALIDATION OF AN AGENTIC LARGE LANGUAGE MODEL (LLM) SYSTEM IN THE REVIEW STAGE OF A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR): A SOLUTION TO INSTANT AND EASY ACCESS TO CLINICAL TRIAL DATA (CTD)
Mar 18, 2026, 21:38 PM -
SURVEY OF ATTITUDES TOWARDS HPV VACCINATION AMONG YOUNG PEOPLE
Mar 18, 2026, 21:38 PM -
ENSURING ESTIMAND AND POPULATION CONSISTENCY ACROSS HEALTH TECHNOLOGY ASSESSMENT DOSSIER COMPONENTS
Mar 18, 2026, 21:38 PM -
THE IMPACT OF DIFFERENT TIME-VARYING NETWORK META-ANALYSIS METHODS TO ASSESS TALAZOPARIB + ENZALUTAMIDE VERSUS OLAPARIB + ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
A COMPARATOR CHOICE SET FRAMEWORK FOR VALUE-BASED PRICING UNDER THE INFLATION REDUCTION ACT
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT AND COST CALCULATOR MODEL FOR POHERDY® (PERTUZUMAB-DPZB) IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER
Mar 18, 2026, 21:38 PM -
TARGET TRIAL EMULATION (TTE) INFORMED BY CLINICAL TRIAL DATA: ADJUVANT NIVOLUMAB VS OBSERVATION IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (RNSCLC) AFTER NEOADJUVANT NIVOLUMAB PLUS CHEMOTHERAPY AND SURGERY
Mar 18, 2026, 21:38 PM
